Each dot is one of the 21 Contract Manufacturing stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 4.1% and the median P/E 27.77. Pinned to the edge: 3 outliers on X and 1 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | TMOThermo Fisher Scientific | 7.2% | 36.20 | $252.21B | Life Sciences Tools |
| 2 | PFEPfizer | -0.2% | 39.18 | $169.74B | Pharmaceuticals |
| 3 | TEVATeva Pharmaceutical Industries | 4.1% | 65.87 | $46.51B | Generic Drugs |
| 4 | ZTSZoetis | 1.5% | 12.84 | $33.60B | Animal Health |
| 5 | WSTWest Pharmaceutical Services | 12.4% | 49.05 | $27.71B | Medical Supplies |
| 6 | IFFInternational Flavors & Fragrances | -4.6% | 34.27 | $23.86B | Specialty Chemicals |
| 7 | STESteris | 8.4% | 27.77 | $22.36B | Medical Devices |
| 8 | RDYDr Reddys Laboratories | -10.5% | 31.48 | $11.44B | Generic Drugs |
| 9 | PODDInsulet | 29.4% | 27.15 | $10.19B | Medical Devices |
| 10 | ALKSAlkermes | 10.8% | 111.85OUT | $7.40B | Pharmaceuticals |
| 11 | LNTHLantheus Holdings | 2.3% | 23.65 | $6.51B | Diagnostic Equipment |
| 12 | LGNDLigand Pharmaceuticals | 54.9%OUT | 31.04 | $6.12B | Biotechnology |
| 13 | LQDALiquidia | 2,234%OUT | 28.47 | $3.95B | Pharmaceuticals |
| 14 | OGNOrganon | -2.5% | 17.27 | $3.61B | Pharmaceuticals |
| 15 | ADMAAdma Biologics | 8.0% | 14.81 | $2.50B | Biotechnology |
| 16 | AMPHAmphastar Pharmaceuticals | 1.0% | 14.11 | $1.11B | Generic Drugs |
| 17 | IARTIntegra Lifesciences Holdings | 0.8% | 71.84 | $934.83M | Medical Devices |
| 18 | MGTXMeiraGTx Holdings | 957.3%OUT | 9.75 | $842.88M | Gene and Cell Therapy |
| 19 | EMBCEmbecta | -7.6% | 4.46 | $390.35M | Medical Devices |
| 20 | ELTPElite Pharmaceuticals | 33.7% | 4.65 | $263.38M | Generic Drugs |
| 21 | UTMDUtah Medical Products | -7.0% | 22.34 | $234.29M | Medical Devices |
Among Contract Manufacturing stocks, the largest companies growing revenue faster than the median (4.1%) while trading below the median P/E (27.77) are Insulet (PODD), Adma Biologics (ADMA), MeiraGTx Holdings (MGTX) and Elite Pharmaceuticals (ELTP). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Pfizer (PFE), International Flavors & Fragrances (IFF), Dr Reddys Laboratories (RDY) and Integra Lifesciences Holdings (IART).
The median P/E across the 21 Contract Manufacturing stocks plotted is 27.77, with the middle half between 14.81 and 36.20.
The median is 4.1%, with the middle half between -0.2% and 12.4%.
The rank correlation (Spearman) is 0.00, a no meaningful positive relationship: knowing one tells you little about the other.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 3 companies are outliers on Revenue Growth (1y) (TTM) and 1 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry is included unless you choose primary industry only. Nothing on this page is investment advice.